Summary

Patients with adrenal insufficiency who were treated with once-daily dual-release oral hydrocortisone experienced significant improvement in natural killer cell levels, body weight, and systolic blood pressure compared with patients who received conventional treatment with cortisone acetate or oral hydrocortisone, regardless of the type of adrenal insufficiency or prior therapy.

  • glucocorticoid
  • hydrocortisone
  • natural killer cells
  • DREAM trial
  • adrenal disorders
  • endocrinology, diabetes & metabolism clinical trials
View Full Text